BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)

Reuters

03/10

March 10 (Reuters) - Keymed Biosciences Inc 2162.HK:

UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901)
ASTRAZENECA INITIATES PHASE III STUDY OF AZD0901 FOR ADVANCED GASTRIC CANCER

Further company coverage: 2162.HK

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618293920"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618293920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618293920?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618293920","market":"nz","top_or_hot":-1,"title":"BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)</title></head><body><p><span>March 10 (Reuters)</span><span> - </span>Keymed Biosciences Inc <span>2162.HK</span>:</p><ul><li><p>UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901)</p></li><li><p>ASTRAZENECA INITIATES PHASE III STUDY OF AZD0901 FOR ADVANCED GASTRIC CANCER</p></li></ul><p>Further company coverage: <span>2162.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-03-10 18:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)</title></head><body><p><span>March 10 (Reuters)</span><span> - </span>Keymed Biosciences Inc <span>2162.HK</span>:</p><ul><li><p>UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901)</p></li><li><p>ASTRAZENECA INITIATES PHASE III STUDY OF AZD0901 FOR ADVANCED GASTRIC CANCER</p></li></ul><p>Further company coverage: <span>2162.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211327993.USD","symbol_name":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nFWN3ZY01X:1","article_id":"2618293920","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618293920","pubTimestamp":1773138525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 March 10  - Keymed Biosciences Inc 2162.HK:UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 ASTRAZENECA INITIATES PHASE III STUDY OF AZD0901 FOR ADVANCED GASTRIC CANCERFurther company coverage: 2162.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU2539964713.USD":"SCHRODER ISF EUROPEAN SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0969580561.USD":"贝莱德欧洲特别时机基金A2","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","AZN.UK":"阿斯利康制药","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","BK5011":"制药","LU0640478417.SGD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AGH\" (SGDHDG) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","02162":"康诺亚-B","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2114397693.USD":"BGF EUROPEAN EQUITY INCOME \"A\" (USDHDG) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","LU1078025761.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2293690082.USD":"SCHRODER ISF EUROPEAN SUSTAINABLE EQUITY \"A\" (USD) INC","03165":"华夏欧优股对冲","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0047473722.EUR":"HSBC GIF EUROPE VALUE \"PD\" (EUR) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU0889565080.SGD":"FTIF - Templeton European Opportunities A Acc SGD-H1","LU0882574055.USD":"富达全球健康医疗A ACC","LU1170363599.USD":"ALLIANZ EUROPE EQUITY GROWTH SELECT \"A\" (USDHDG) INC","LU0499090636.EUR":"AZ FUND 1 DIVIDEND PREMIUM \"A-AZ\" ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0857590862.USD":"ALLIANZ EUROPE EQUITY GROWTH \"AT\" (USDHDG) H2 ACC","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU2091194634.USD":"BGF EUROPEAN EQUITY INCOME \"A2\" (USD) ACC","BK1583":"高瓴概念","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H"},"translate_title":"简介-Keymed Biosciences与阿斯利康合作核心产品CMG901(AZD0901)的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9,"AZN.UK":0.9,"03165":0.6},"content_text":"BRIEF-Keymed Biosciences Updates On Collaboration With Astrazeneca On Core Product CMG901 (AZD0901)March 10 (Reuters) - Keymed Biosciences Inc 2162.HK:UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901)ASTRAZENECA INITIATES PHASE III STUDY OF AZD0901 FOR ADVANCED GASTRIC CANCERFurther company coverage: 2162.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}